Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Lt. Gen. Herzi Halevi is the most senior Israeli figure to resign over the security and intelligence breakdown on Oct. 7, 2023, when thousands of Hamas-led militants carried out a land ...

The company says that in pre-clinical tests performed on 30 people with macular degeneration, all of the participants experienced a reading speed increase of at least 50% when using the glasses.

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME) has been dosed. The company describes OCU200 as a “recombinant fusion protein that consists of ...

The current Phase 2 study in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients is studying the proprietary nanomedicine, migaldendranib, which is subcutaneously ...